204 related articles for article (PubMed ID: 37522923)
1. Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma.
Drechsel KCE; Broer SL; Stoutjesdijk FS; Twisk JWR; van den Berg MH; Lambalk CB; van Leeuwen FE; Overbeek A; van den Heuvel-Eibrink MM; van Dorp W; de Vries ACH; Loonen JJ; van der Pal HJ; Kremer LC; Tissing WJ; Versluys B; Kaspers GJL; van Dulmen-den Broeder E; Veening MA;
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13677-13695. PubMed ID: 37522923
[TBL] [Abstract][Full Text] [Related]
2. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review.
Drechsel KCE; Pilon MCF; Stoutjesdijk F; Meivis S; Schoonmade LJ; Wallace WHB; van Dulmen-den Broeder E; Beishuizen A; Kaspers GJL; Broer SL; Veening MA
Hum Reprod Update; 2023 Jul; 29(4):486-517. PubMed ID: 36779325
[TBL] [Abstract][Full Text] [Related]
3. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.
van den Berg MH; Overbeek A; Lambalk CB; Kaspers GJL; Bresters D; van den Heuvel-Eibrink MM; Kremer LC; Loonen JJ; van der Pal HJ; Ronckers CM; Tissing WJE; Versluys AB; van der Heiden-van der Loo M; Heijboer AC; Hauptmann M; Twisk JWR; Laven JSE; Beerendonk CCM; van Leeuwen FE; van Dulmen-den Broeder E;
Hum Reprod; 2018 Aug; 33(8):1474-1488. PubMed ID: 29982673
[TBL] [Abstract][Full Text] [Related]
5. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
6. Low Anti-Müllerian Hormone in Pediatric Cancer Survivors in the Early Years after Gonadotoxic Therapy.
Elchuri SV; Patterson BC; Brown M; Bedient C; Record E; Wasilewski-Masker K; Mertens AC; Meacham LR
J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):393-9. PubMed ID: 26924632
[TBL] [Abstract][Full Text] [Related]
7. Female reproductive function after treatment of childhood acute lymphoblastic leukemia.
Roshandel R; van Dijk M; Overbeek A; Kaspers G; Lambalk C; Beerendonk C; Bresters D; van der Heiden-van der Loo M; van den Heuvel-Eibrink M; Kremer L; Loonen J; van der Pal H; Ronckers C; Tissing W; Versluys B; van Leeuwen F; van den Berg M; van Dulmen-den Broeder E;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28894. PubMed ID: 33459500
[TBL] [Abstract][Full Text] [Related]
8. Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
Parissone F; Di Paola R; Balter R; Garzon S; Zaffagnini S; Neri M; Vitale V; Tridello G; Cesaro S
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):25-33. PubMed ID: 33068384
[TBL] [Abstract][Full Text] [Related]
9. Low ovarian reserve and risk of miscarriage in pregnancies derived from assisted reproductive technology.
Chinè A; Reschini M; Fornelli G; Basili L; Busnelli A; Viganò P; Muzii L; Somigliana E
Hum Reprod Open; 2023; 2023(3):hoad026. PubMed ID: 37287447
[TBL] [Abstract][Full Text] [Related]
10. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.
Shandley LM; Fothergill A; Spencer JB; Mertens AC; Cottrell HN; Howards PP
Fertil Steril; 2018 Mar; 109(3):516-525.e1. PubMed ID: 29428311
[TBL] [Abstract][Full Text] [Related]
11. Impact of cancer therapies on ovarian reserve.
Gracia CR; Sammel MD; Freeman E; Prewitt M; Carlson C; Ray A; Vance A; Ginsberg JP
Fertil Steril; 2012 Jan; 97(1):134-40.e1. PubMed ID: 22137491
[TBL] [Abstract][Full Text] [Related]
12. Ovarian reserve in reproductive-aged patients with cancer before gonadotoxic treatment: a systematic review and meta-analysis.
Wu M; Zhu Q; Huang Y; Tang W; Dai J; Guo Y; Xiong J; Zhang J; Zhou S; Fu F; Wu M; Wang S
Hum Reprod Open; 2023; 2023(3):hoad024. PubMed ID: 37325546
[TBL] [Abstract][Full Text] [Related]
13. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization.
Lukaszuk K; Kunicki M; Liss J; Lukaszuk M; Jakiel G
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):173-7. PubMed ID: 23485092
[TBL] [Abstract][Full Text] [Related]
14. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
15. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
[TBL] [Abstract][Full Text] [Related]
16. [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
Krawczuk-Rybak M; Leszczyńska E; Wysocka J; Zelazowska-Rutkowska B
Pediatr Endocrinol Diabetes Metab; 2008; 14(2):99-103. PubMed ID: 18721496
[TBL] [Abstract][Full Text] [Related]
17. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
[TBL] [Abstract][Full Text] [Related]
18. Anti-müllerian hormone compared with other ovarian markers after childhood cancer treatment.
Nyström A; Mörse H; Nordlöf H; Wiebe K; Artman M; Øra I; Giwercman A; Henic E; Elfving M
Acta Oncol; 2019 Feb; 58(2):218-224. PubMed ID: 30558460
[TBL] [Abstract][Full Text] [Related]
19. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?
Muttukrishna S; McGarrigle H; Wakim R; Khadum I; Ranieri DM; Serhal P
BJOG; 2005 Oct; 112(10):1384-90. PubMed ID: 16167941
[TBL] [Abstract][Full Text] [Related]
20. Dose-Effect Relationship of Alkylating Agents on Testicular Function in Male Survivors of Childhood Lymphoma.
Servitzoglou M; De Vathaire F; Oberlin O; Patte C; Thomas-Teinturier C
Pediatr Hematol Oncol; 2015; 32(8):613-23. PubMed ID: 26561347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
